|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Corcept Therapeutics, Inc.
| | | Phone: | (650) 327-3270 | Fax: | (650) 327-3218 | Year Established: | 1998 | Ticker: | CORT | Exchange: | NASDAQ | Main Contact: | Sean Maduck, Senior VP, Commercial | | Other Contacts: | J.D. Lyon, VP, Corporate Controller Charles Robb, CFO Susan Rinne, VP, Corporate Regulatory Affairs Hazel Hunt, Ph.D., VP, Research Carolyn Hobbs, VP, Corporate Affairs Robert S. Fishman, MD, CMO Thaddeus S. Block, MD, VP, Clinical Development Joseph K. Belanoff, M.D., President & CEO
| | Company Description | Corcept Therapeutics is a leader in the discovery and development of drugs that regulate the effects of cortisol. Corcept’s scientific expertise surrounding the regulation of cortisol has led to the discovery of an extensive library of novel compounds that may ultimately address numerous important diseases through the blockade of the cortisol receptor. Corcept’s most advanced pipeline product is CORLUX. The company has completed patient dosing and announced positive top-line results from a Phase 3 study in Cushing’s Syndrome and they are conducting a Phase 3 study in psychotic depression. | |
|
|
|
|
|